Evidence map›Paper›PMID 35138414›Full record

ReviewDer Urologe. Ausg. A2022

[Prostate-specific membrane antigen positron emission tomography (PSMA PET) for urologists-when and which tracer?]

Christoph Berliner, Claudia Kesch, Wolfgang P Fendler, Matthias Eiber, Tobias Maurer

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Urologe. Ausg. A, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Christoph BerlinerKlinik für Nuklearmedizin, Universitätsklinikum Essen, Hufelandstr. 55, 45147, Essen, Deutschland. christoph.berliner@uk-essen.de.ORCID http://orcid.org/0000-0001-9201-8803
Claudia KeschKlinik für Urologie, Universitätsklinikum Essen, Essen, Deutschland.
Wolfgang P FendlerKlinik für Nuklearmedizin, Universitätsklinikum Essen, Hufelandstr. 55, 45147, Essen, Deutschland.
Matthias EiberKlinik für Nuklearmedizin, Klinikum Rechts , der Isar, Technische Universität München, München, Deutschland.
Tobias MaurerMartini-Klinik Prostatakrebszentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProstate-specific membrane antigen positron emission tomography (PSMA PET) is increasingly replacing conventional imaging for staging of prostate cancer. A major challenge is its appropriate use and correct interpretation.

objectivesHow and when is PSMA PET used in patient care to optimally direct therapy? MATERIALS AND

methodsSystematic presentation and discussion of the current state of knowledge, guidelines and expert knowledge on PSMA PET with a summary of ongoing studies.

conclusionPSMA PET is the new standard for systemic staging of prostate cancer, enabling precision patient care with novel local, oligometastatic, and systemic treatment approaches.

Indexed as

ProstateProstatic NeoplasmsHumansMaleNeoplasm StagingPositron-Emission TomographyPositron Emission Tomography Computed TomographyProstate-Specific AntigenUrologistsProstate-Specific AntigenNeoplasm metastasisProstate carcinomaRadioligand therapyRecurrenceStaging

Identifiers

PMID35138414

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.